Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644021 | 0.95 | KMT2A (0.42) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| SCHEMBL4610177 | 0.93 | EPHX1 (0.45) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| SCHEMBL111091 | 0.93 | EPHX1 (0.45) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| SCHEMBL643110 | 0.93 | EPHX1 (0.45) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| SCHEMBL10814953 | 0.93 | EPHX1 (0.45) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| SCHEMBL2533403 | 0.90 | TET2 (0.36) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| SCHEMBL1134203 | 0.90 | — | — | |
| SCHEMBL3211932 | 0.83 | — | — | |
| SCHEMBL23644810 | 0.82 | EPHX1 (0.38) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| SCHEMBL10818793 | 0.82 | CYP1A2 (0.32) | SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-1896452-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8044199-B2 | N-formyl hydroxylamines compounds | VICURON HOLDINGS LLC (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044199-B2 | N-formyl hydroxylamines compounds | VICURON HOLDINGS LLC (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044199-B2 | N-formyl hydroxylamines compounds | VICURON HOLDINGS LLC (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | NOVARTIS AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | NOVARTIS AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | NOVARTIS AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-7615635-B2 | N-formyl hydroxylamines | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-7615635-B2 | N-formyl hydroxylamines | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | LEE KWANGHO | 2009-03-05 | — | — | US | disclosed |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | LEE KWANGHO | 2009-03-05 | — | — | US | disclosed |
| EP-1994027-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| EP-1896452-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis Pharma AG. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007106670-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106670-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006127576-A2 | N - FORMYL HYDROXYLAMINE COMPOUNDS AS PDF INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | PDF, MMP2, HNMT | KMT2A 2065/4885EPHX1 1858/4885HPGD 94/4885 |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | PDF, HNMT, MMP2 | KMT2A 2308/4885EPHX1 1652/4885HPGD 66/4885 |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | PDF, MMP2, PEPD | KMT2A 2681/4885EPHX1 1770/4885HPGD 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.